Table 1 Demographic characteristics and clinical data of the study cohort at baseline.
Number of patients | 220 |
|---|---|
Men/female, n | 150:70 |
Age, years ± SD | 71.3 ± 9.2 |
Diabetes duration, years ± SD | 12.4 ± 4.6 |
BMI, Kg/m2 ± SD | 29.5 ± 3.0 |
Smoking (current), n (%) | 61 (27.7) |
Smoking (former), n (%) | 68 (30.9) |
Never smoked, n (%) | 91 (41.4) |
Hypertension, n (%) | 120 (54.5) |
Hypercholesterolemia, n (%) | 100 (45.4) |
CAD, n (%) | 102 (46.4) |
CVD, n (%) | 45 (20.4) |
Lipid-lowering agent | 178 (80.9) |
ACE inhibitor or ARB | 165 (75.0) |
ABI, ± SD | 0.39 ± 0.1 |
Rutherford II-4, n (%) | 121 (55.0) |
Rutherford III-5, n (%) | 99 (45.0) |
WIfI010, n (%) | 99 (45.0) |
WIfI020, n (%) | 35 (15.9) |
WIfI110, n (%) | 62 (28.2) |
WIfI120, n (%) | 107 (48.6) |
HbA1c, % ± SD | 8.8 ± 1.5 |
FBG, mg/dL ± SD | 114.1 ± 19.8 |
Total cholesterol, mg/dL ± SD | 204.1 ± 29.3 |
LDL cholesterol, mg/dL ± SD | 100.7 ± 19.4 |
Triglycerides, mg/dL ± SD | 212.2 ± 36.9 |
Creatinine, mg/dL ± SD | 1.4 ± 0.4 |
eGFR, mL/min/1.73m2 ± SD | 64.4 ± 14.6 |
Ca, mg/dL ± SD | 9.5 ± 0.8 |
Ph, mg/dL ± SD | 3.7 ± 0.8 |
Vitamin D, ng/mL ± SD | 48.5 ± 15.9 |
Klotho, pg/mL ± SD | 403.1 ± 179.3 |
FGF23 pg/mL ± SD | 59.4 ± 17.5 |
